ExoCordOA EV-enriched secretome from cord blood as a new disease modifying treatment for osteoarthritis
- Coordinator
- Exogenus Therapeutics SA, Portugal
- Runs
- 1 September 2026 to 31 August 2031
- Status
- Running
- EU funding
- €13.0m
- Total cost
- €13.0m
- Partners
- 10 organisations in 3 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101288259
What the project is doing
In the project's own words, from its summary on CORDIS.
ExoCordOA is a flagship initiative to advance secretome-based therapies through two complementary pillars: (1) the clinical development of Exo-101 for osteoarthritis (OA), and (2) the resolution of systemic bottlenecks that limit broader adoption of secretome medicines. Exo-101, a first-in-class extracellular vesicle (EV)-enriched secretome derived from umbilical cord blood, has demonstrated robust anti-inflammatory, immunomodulatory, and regenerative effects in preclinical models of OA.
ExoCordOA will advance Exo-101 GMP-manufacturing, GLP preclinical safety validation, and all the regulatory and clinical activities needed to finalise Phase I and II clinical trials during the project lifetime. Ultimately, this project will advance Exo-101 towards Phase III post-project, potentially positioning it as Europe’s first clinically validated secretome therapy for OA. In parallel, the project addresses the systemic bottlenecks that hinder broad adoption of EV-based medicines.
It will establish a GMP-compliant manufacturing process, develop integrated quality control combining AI-enhanced optical fingerprinting with multi-omics profiling, and support implementation of clinically relevant potency assays based on deep EV characterization in biological fluids. Furthermore, by convening a regulatory forum of international experts, ExoCordOA will provide an evidence-based framework to inform future approvals of secretome therapies.
Bringing together biotech innovators, clinical trial experts, hospitals, CROs, GMP manufacturers, regulators, academics, a cord blood bank, market experts and patient representatives, the consortium has the expertise and infrastructure to deliver a disease-modifying treatment for OA while building the foundations for Europe’s leadership in secretome-based therapeutics.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Exogenus Therapeutics SA | Cantanhede | Portugal | Coordinator |
| Academisch Ziekenhuis Maastricht | Maastricht | Netherlands | Participant |
| Lonza Netherlands BV | Maastricht | Netherlands | Participant |
| Stichting ReumaNederland | Amsterdam | Netherlands | Participant |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Universiteit Utrecht | Utrecht | Netherlands | Participant |
| Ilof - Intelligent Lab on Fiber, Unipessoal Lda | Matosinhos | Portugal | Participant |
| Anthony Nolan | London | United Kingdom | Participant |
| Eliquent Life Sciences, U.K., Ltd. | Camberley | United Kingdom | Participant |
| Image Analysis Limited | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI